Provider incentives and prescribing behavior in Europe

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 5, Issue 1, 2005, Pages 81-93

  Mossialos, Elias ^a   Walley, Tom ^b   Rudisill, Caroline ^a  

^a LONDON SCHOOL OF ECONOMICS   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Doctors; Europe; Incentives; Prescribing

Indexed keywords

GENERIC DRUG;

AUSTRIA; BUDGET; CHRONIC DISEASE; COST EFFECTIVENESS ANALYSIS; DRUG COST; EUROPE; FINANCIAL MANAGEMENT; FRANCE; GENERAL PRACTITIONER; GERMANY; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE FINANCING; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HEALTH PRACTITIONER; HUMAN; INDIVIDUALIZATION; IRELAND; MEDICAL DECISION MAKING; MEDICAL ETHICS; MEDICAL INFORMATION SYSTEM; NATIONAL HEALTH SERVICE; PHARMACEUTICAL CARE; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; PRESCRIPTION; REVIEW; REWARD; UNITED KINGDOM;

EID: 17844363945     PISSN: 14737167     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737167.5.1.81     Document Type: Review

References (51)

1. Department of Health. Improving Prescribing. HMSO, London, UK (1990).
2. Le Grand J, Mays N, Mulligan J. Learning from the NHS Internal Market: a Review of the Evidence. King's Fund. London, UK (1998).
3. Chaix-Couturier C, Durand-Zaleski I, Jolly D et al. Effects of financial incentives on medical practice: results from a systematic review of the literature and methodological issues. Int. J. Qual. Health Care 12, 133-142 (2000).
4. Mossialos E, Le Grand J. Health Care and Cost Containment in the European Union. Ashgate, Aldershot, UK (1999).
5. Lopez-Bastida J, Mossialos E. Pharmaceutical expenditure in Spain: cost and control. Int. J. Health Serv. 30, 597-616 (2000).
6. Donatini A, Rico A. Health Care Systems in Transition: Italy. European Observatory on Health Care Systems, Copenhagen, Denmark (2001).
7. Majeed A, Evans N, Head P. What can PACT tell us about prescribing in general practice? Br. Med. J. 315, 1515-1519 (1997).
8. Bellingham C. Prescribing: pace of change continues. Pharm. J. 273, 91 (2004).
9. Harris CM, Scrivener G. Fundholders' prescribing costs: the first five years. Br. Med. J. 313, 1531-1534 (1996).
10. Wilson RP, Hatcher J, Barton S et al. General practice fundholders' prescribing savings in one region of the United Kingdom, 1991-1994. Health Pol. 42, 29-37 (1997).
11. Matsaganis M, Glennerster H. The threat of "cream skimming" in the post-reform NHS. J. Health Econ. 13, 31-60 (1994).
12. Tobin MD, Packham CJ. Can primary care groups learn how to manage demand from fundholders? A study of fundholders in Nottingham. Br. J. Gen. Prac. 49, 291-294 (1999).
13. Gosden T, Torgerson DJ. The effect of fundholding on prescribing and referral costs: a review of the evidence. Health Pol. 40, 103-114 (1997).
14. Carthy P, Harvey I, Brawn R et al. A study of factors associated with costs and variation in prescribing among GPs. Fam. Practice 17(1), 36-41 (2000).
15. Audit Commission. A Prescription for Improvement: Towards More Rational Prescribing in General Practice. HMSO, London, UK (1994).
16. Bateman DN, Campbell M, Donaldson LJ et al. A prescribing incentive scheme for non-fundholding general practices: an observational study. Br. Med. J. 313, 535-538 (1996).
17. Ashworth M, Armstrong D, Colwill S et al. Motivating general practitioners to change their prescribing: the incentive of working together. J. Clin. Pharm. Ther. 25, 119-124 (2000).
18. Ashworth M, Lea R, Gray H et al. How are primary care organizations using financial incentives to influence prescribing? J. Pub. Health 26(1), 48-51 (2004).
19. Mason A, Towse A, Drummond M et al. Influencing Prescribing in Primary Care Led NHS. Office of Health Economics, London, UK (2003).
20. Ashworth M, Golding S, Shepherd L et al. Prescribing incentive schemes in two NHS regions: cross sectional survey. Commentary: prescribing incentive schemes - more evidence is needed of how they work. Br. Med. J. 324, 1187-1188 (2002).
21. Roland M. Linking physicians' pay to the quality of care - a major experiment in the United Kingdom. N. Engl. J. Med. 351(14), 1448-1453 (2004).
22. Walley T, Mrazek M, Mossialos E. Regulating pharmaceutical markets: improving efficiency and controlling costs in the UK. Int. J. Health Plan. Management (2005) (In Press).
23. Delnoij D, Brenner G. Importing budget systems from other countries: what can we learn from the German drug budget and the British GP fundholding? Health Pol. 52, 157-169 (2000).
24. Busse R, Howerth C. Cost containment in Germany: twenty years experience. In: Health Care and Cost Containment in European Union. Mossialos E, Le Grand J (Eds). Ashgate, Aldershot, UK (1999).
25. Busse R. Health Care Systems in Transition: Germany. European Observatory on Health Care Systems, Copenhagen, Denmark (2000).
26. Junger C, Rathmann W, Gianni C. Prescribing behavior of primary care physicians in diabetes therapy: effect of drug budgeting. Ditsch Med. Wochenschr. 125, 103-109 (2000).
27. Weltermann B, Martin C, Adl S et al. Prescribing practice for β-blockers at patient discharge to ambulatory care. A health care economic evaluation in a cardiology patient sample with special reference to drug budgeting. Gesundheitswesen 59, 258-261 (1997).
28. MMW. Erhebliche Defizite bei der Arzneimittelversorgung. MMW-Fortschritte der Medizin 143, 43 (2001).
29. Schoffski O, Graf von der Schulenburg JM. Unintended effects of a cost-containment policy: results of a natural experiment in Germany, Social Sci. Med. 45, 1537-1539 (1997).
30. Schoffski O. Consequences of implementing a drug budget for office-based physicians in Germany. PharmacoEconomics 10(Suppl. 2), 37-47 (1996).
31. Busse R, Henke K, Schreyogg J. Regulation of pharmaceutical markets in Germany: improving efficiency and controlling expenditures. Int. J. Health Plan. Management (2005) (In Press).
32. Presse-und Informationsamt der Bundersregierung. Sozialpolitische Umschau. Presse-und Informationsamt der Bundersregierung Berlin, Germany (2002).
33. Dietrich ES. Arzneimitteldaten; das drama der späten lieferung. DeutschesÄrzteblatt 97, A-3321 (2000).
34. Jacker A. Alternativen zu arzneimittelbudgets. Pharmazeutische Industrie 62, 74-143 (2000).
35. Schwermann T, Greiner W, Schulenburg VD. Using disease management and market reforms to address the adverse economic effects of drug budgets and price and reimbursement regulations in Germany. Value Health 6(Suppl. 1), S20-S30 (2003).
36. Korzilius H. Arzneimittelbudget: die zeit danach. Deutsches Arzteblatt 98, A-2844 (2001).
37. Sperschneider T, Kleinert S. Germany's sick health-care system. Lancet 360, 1758 (2002).
38. Taxis K, Schneeweiss S. Frequency and predictors of drug therapy interruptions after hospital discharge under physician drug budgets in Germany. Int. J. Clin. Pharmacol. Ther. 41(2), 77-82 (2002).
39. Walley T, Murphy M, Codd M et al. Effects of a monetary incentive on primary care prescribing in Ireland: changes in prescribing patterns in one health Board 1990-1995. Pharmacoepidemiol. Drug Safety 9, 591-598 (2000).
40. Comptroller and Auditor General. Prescribing Practices and the Development of General Practitioner Services. Comptroller and Auditor General (John Purcell), Department of Health and Children, Dublin, Ireland (1997).
41. Durieux P. The Introduction of Regulatory Practice Guidelines in the French Health Care System. Paper Presented at The Conference on European Integration and Health Care Systems: a Challenge for Social Policy, 1-8 (2001).
42. Durieux P, Gaillac B, Giraudeau B et al. Despite financial penalties, French physicians' knowledge of regulatory practice guidelines is poor. Arch. Fam. Med. 9, 414-418 (2000).
43. Durieux P, Chaix-Couturier C, Durand-Zaleski I et al. From clinical recommendations to mandatory practice: the introduction of regulatory practice guidelines in the French healthcare system. Int. J. Technol. Assess. Health Care 16, 969-975 (2000).
44. Paraponaris A, Verger P, Desquins B et al. Delivering generics without regulatory incentives? Empirical evidence from French general practitioners about willingness to prescribe international non-proprietary names. Health Pol. 70, 23-32 (2004).
45. Sandier S, Polton D, Paris V. Health Care Systems in Transition: France. European Observatory on Health Care Systems, Copenhagen, Denmark (2004).
46. CNAMTS. Les Médicaments Remboursés par le Régime d'Assurance Maladie au Cours du Premier Semestre 1999 et u Premier Semestre 2000 (MEDICAM). CNAMTS, Paris, France (2001).
47. Mair A. Maßnahmen der ÖGAK zur Eindämmung der Steigerungsraten bei den Medikamentenausgaben. Regional health insurer for Oberösterreich. (2005) (In Press).
48. Fattore G, Jommi C. The new pharmaceutical policy in Italy. Health Pol. 46(1), 21-41 (1998).
49. Grumbach K, Osmond D, Vranizan K et al. Primary care physicians' experience of financial incentives in managed-care systems. N. Engl. J. Med. 339, 1516-1521 (1998).
50. Sulmasy DP, Bloche MG, Mitchell JM et al. Physicians' ethical beliefs about cost-control arrangements. Arch. Intern. Med. 160, 649-657 (2000).
51. Walley T, Murphy M, Codd M et al. Effects of a monetary incentive on primary care prescribing in Ireland: attitudes and perceptions of health care professionals and patients. Eur. J. Gen. Practice 7, 92-98 (2001).